Doctors Recommend A New Treatment For Cancer

Doctors Recommend A New Treatment For Cancer.
The sedative Arimidex reduces the imperil of developing breast cancer by more than 50 percent among postmenopausal women at apex risk for the disease, according to a new study Dec 2013. The finding, scheduled for visual Thursday at the San Antonio Breast Cancer Symposium in Texas, adds look forward to that Arimidex (anastrozole) might be a valuable new preventive option for some women. The enquiry will also be published in the journal The Lancet.

So "Two other antihormone therapies, tamoxifen and raloxifene, are reach-me-down by some women to prevent breast cancer, but these drugs are not as effective and can have adverse side effects, which hold in check their use," study lead author Jack Cuzick said in a new release from the American Association for Cancer Research. "Hopefully, our findings will pre-eminence to an alternative prevention therapy with fewer ancillary effects for postmenopausal women at high risk for developing breast cancer," said Cuzick, aim of the Cancer Research UK Centre for Cancer Prevention and director of the Wolfson Institute of Preventive Medicine at Queen Mary University of London.

About 80 percent of US teat cancer patients have tumors with boisterous levels of hormone receptors, and these tumors are fueled by the hormone estrogen. Arimidex prevents the body from making estrogen and is therefore employed to treat postmenopausal women with hormone receptor-positive core cancer. The study included more than 3800 postmenopausal women at increased gamble for breast cancer due to having two or more blood relatives with breast cancer, having a mummy or sister who developed breast cancer before age 50, or having a spoil or sister who had breast cancer in both breasts.

Sustainable Increase In Weight Increases In The Later Stages Of The Life Risk Of Breast Cancer

Sustainable Increase In Weight Increases In The Later Stages Of The Life Risk Of Breast Cancer.
Women who packet on the pounds over their lifetime steadily broaden their imperil for postmenopausal breast cancer, compared with women who announce their weight, a new study finds. Earlier studies have linked excess weight with an increased hazard for breast cancer in postmenopausal women, but this is one of the few studies that traces the risk as a function of importance gain over time.

So "Among women who had never used postmenopausal hormone therapy, those who had a body-mass listing (BMI) gain between age 20 and 50 had a doubling of breast cancer risk," said example researcher Laura Sue, a cancer research fellow at the US National Cancer Institute. Sue was expected to confer the findings Tuesday at the American Association for Cancer Research's annual meeting, in Washington DC.

For the study, Sue's side collected data on more than 72000 women who took say in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. When the exploration began, the women were between 55 and 74 years old. Among these women, 3677 had developed a postmenopausal knocker cancer.